Start here if you're new
what it is
Definitive Healthcare sells healthcare market data and software that helps drug, device, and health tech companies find customers.
how it gets paid
Last year Definitive Health made $242M in revenue. sales intelligence was the main engine at $87M, or 36% of sales.
why growth slowed
Revenue fell 4.2% last year. The number that mattered was 75.8% gross margin.
what just happened
Revenue hit $180M, but EPS was still a loss at -$1.20.
At a glance
C++ balance sheet — some cracks in the foundation
22.0% return on capital — every dollar works hard here
$1.21 fy2024 eps est
$252M fy2024 rev est
92.9% operating margin
xvary composite: 32/100 — weak
What they do
Definitive Healthcare sells healthcare market data and software that helps drug, device, and health tech companies find customers.
The product is sticky because your sales team does not want to rebuild a healthcare contact map from scratch. The platform bundles 14 intelligence modules into one workflow, which saves time when you are selling into hospitals, physicians, and health systems. That matters because gross margin was 75.8% in the latest SEC filing, which means the data itself is cheap to deliver once customers stay.
How they make money
$242M
annual revenue · their business grew -4.2% last year
sales intelligence
$87M
marketing intelligence
$53M
clinical research and product development
$44M
strategy intelligence
$34M
talent and network management
$24M
The products that matter
provider data subscriptions
Subscription revenue
$229M · 94.6% of revenue
This is the whole story. It generated $229M last year, or 94.6% of revenue, and still declined 4.2%.
core
implementation and support work
Professional services & other
$13M · 5.4% of revenue
It's only $13M, so even big improvement here won't fix the investment case on its own. The core subscription line has to stabilize first.
too small to move it
retention and expansion motion
Upsell and cross-sell
2026 management focus
Management is leaning on retention and account expansion to offset a 6%–9% revenue decline. That's the plan. The numbers have not confirmed it yet.
watch closely
Key numbers
$1.21
FY2024 EPS est.
Projected earnings are $1.21 a share, while trailing EPS is -$0.56 from Yahoo Finance. You are buying a turnaround story, not today's income statement.
92.9%
operating margin
Operating margin → profit after running the business → so what: DH loses about $0.93 for every $1 of revenue.
$164M
long-term debt
Debt is larger than the company's roughly $118M market cap. That is the kind of contrast equity holders usually do not enjoy.
75.8%
gross margin
Gross margin → money left after delivering the product → so what: the data product itself is attractive, even if the rest of the cost structure is not.
Financial health
C++
strength
- balance sheet grade C++ — below average — limited financial resources
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
- long-term debt $164M (58% of capital)
C++ — balance sheet grade and long-term debt are flagged. this stock carries more risk than average.
Total return vs. market
Return history isn't available for DH right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Revenue hit $180M, but EPS was still a loss at -$1.20.
Revenue rose 200% vs. prior year in the latest quarter, while annual revenue still fell 4.2% to $242M. That is the quiet part out loud: a big quarter did not fix the full-year trend.
$180M
revenue
$1.20
eps
75.8%
gross margin
the number that mattered
The number that mattered was 75.8% gross margin, because it says the product is strong enough to make money if management ever gets operating costs under control.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is subscription revenue continuing to contract while debt stays heavy.
high
guided revenue decline
Management expects 2026 revenue to fall 6%–9%. For a software business with a weak 32 / 100 composite score, that's the core problem, not a side note.
This directly pressures valuation support for a company already down hard from its highs.
med
debt relative to size
Long-term debt is $164M, or 58% of capital, against a market cap of about $118M. That's a mismatch you can't ignore.
If the revenue reset lasts longer than management expects, balance sheet pressure gets louder.
med
retention and upsell execution
Management is leaning on retention and cross-sell to stabilize results. The data we have does not yet show that working at scale.
If subscription revenue stays negative after those efforts, the turnaround case weakens fast.
low
thin visibility on competitive edge
The margins say the product has value. The declining top line says that value is not translating into durable growth right now.
A 75.8% gross margin business can still be a bad stock if customers are not expanding.
A 6%–9% revenue decline would hit the part of the business that generates 94.6% of sales, while $164M of long-term debt limits room for a slow recovery.
source: institutional data · regulatory filings · risk analysis
Pay attention to
core metric
subscription revenue has to stop shrinking
It was $229M last year, or 94.6% of revenue, and declined 4.2%. If that line stays negative, the rest of the story barely matters.
balance sheet
debt cannot become the story
$164M of long-term debt against a $118M market cap is already uncomfortable. Another year of declining revenue would make it harder to shrug off.
next catalyst
the next earnings report needs more than a small beat
Q4 beat by 3.26%. The next print needs to show that guidance was conservative, not prophetic.
trend line
watch whether margins stay high while revenue falls
75.8% gross margin and 22.7% operating margin are the reason this name still has a turnaround argument. If margins crack too, the thesis gets much harder.
Analyst rankings
risk rank
5
safer than 5% of stocks. in human-speak, the market sees this as a high-risk name.
balance sheet
C++
Below-average balance sheet grade. You're not buying this for safety.
price stability
5 / 100
The stock has been highly unstable. Expect sharp moves if results disappoint or surprise.
source: institutional data
Institutional activity
institutional ownership data for DH is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$3
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive